Drug Approval | March 22, 2022
Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
Using Orion, pharmaceutical and biotechnology companies, as well as any industrial researcher who wishes to perform electronic structure calculations, can gain access to elastic and flexible computational resources in the Cloud
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Women's health is in fact a direct reflection of the nation's overall health
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Subscribe To Our Newsletter & Stay Updated
